2011 Scrip Asia 100 - TeloVac tailwind helps KAEL-GemVax chart a course to market
This article was originally published in Scrip
Executive Summary
Being part of a large listed group relieves KAEL-GemVax from the constant fundraising headaches typical of its peers, writes Ian Haydock. This article is part of the 2011 Scrip Asia 100.